H. Schnebli

发表

Chelator‐induced iron excretion in iron‐overloaded marmosets

T. Sergejew, P. Forgiarini, H. Schnebli, 2000, British journal of haematology.

Isolation and characterization of an enkephalin-degrading aminopeptidase from rat brain.

R. Barclay, H. Schnebli, M. Phillipps, 1979, Biochimica et biophysica acta.

THIOSULPHATE-SULPHUR TRANSFERASE (RHODANESE) DEFICIENCY IN LEBER'S HEREDITARY OPTIC ATROPHY

K. Rhyner, B. Cagianut, H. Schnebli, 1981, The Lancet.

Purine ribonucleoside kinase activity and resistance to some analogs of adenosine.

J. Montgomery, L. Bennett, P. Allan, 1966, Molecular pharmacology.

Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa.

M. Sponer, H. Nick, H. Schnebli, 1991, Biological chemistry Hoppe-Seyler.

Cigarette smoke components are not very effective in directly inactivating alpha 1-proteinase inhibitor.

G. Virca, A. Wyss, H. Schnebli, 1984, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium.

R. F. Hoyt, R. Crystal, C. Vogelmeier, 1990, Journal of applied physiology.

Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats.

R. Thompson, S. Eisenberg, A. Gast, 1990, The American review of respiratory disease.

Effect of different elastase inhibitors on leukocyte elastase pre-adsorbed to elastin.

W. Hornebeck, H. Schnebli, Schnebli Hp, 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis.

S. Suter, U. Schaad, J. Morgenthaler, 1988, The Journal of infectious diseases.

Binding of the recombinant proteinase inhibitor eglin c, of the soybean Bowman-Birk proteinase inhibitor and of its chymotrypsin and trypsin inhibiting fragments to Leu-proteinase, the leucine specific serine proteinase from spinach (Spinacia oleracea L.) leaves: thermodynamic study.

M. Bolognesi, E. Menegatti, A. Ballio, 1991, Journal of enzyme inhibition.

Interaction of Eglin c with polymorphonuclear cells: evidence for binding to the cell surface.

N. J. Braun, H. Schnebli, 1987, Biological chemistry Hoppe-Seyler.

Free radicals inactivate human neutrophil elastase and its inhibitors with comparable efficiency.

R. Dean, H. Nick, H. Schnebli, 1989, Biochemical and biophysical research communications.

Selective inhibition of growth of transformed cells by protease inhibitors.

H. Schnebli, M. Burger, 1972, Proceedings of the National Academy of Sciences of the United States of America.

Membrane adenosine triphosphatase from Streptococcus faecalis. Molecular weight, subunit structure, and amino acid composition.

A. Abrams, A. Vatter, H. Schnebli, 1970, The Journal of biological chemistry.

Membrane adenosine triphosphatase from Streptococcus faecalis. Preparation and homogeneity.

A. Abrams, H. Schnebli, 1970, The Journal of biological chemistry.

Quantitation of human leukocyte elastase, cathepsin G, alpha-2-macroglobulin and alpha-1-proteinase inhibitor in osteoarthrosis and rheumatoid arthritis synovial fluids.

M. Pepys, G. Virca, R. Mallya, 1984, Advances in experimental medicine and biology.

Subunit structure of the rat alpha-macroglobulin proteinase inhibitors.

L. Nelles, H. Schnebli, 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Plasma levels of inhibitor-bound leukocytic elastase in rheumatoid arthritis patients.

M. Pepys, M. Jochum, R. Mallya, 1984, Advances in experimental medicine and biology.

Recombinant Elastase Inhibitors for Therapy

H. Schnebli, 1991, Annals of the New York Academy of Sciences.

Eukaryote ribosomes possess a binding site for concanavalin A.

G. Howard, H. Schnebli, 1977, Proceedings of the National Academy of Sciences of the United States of America.

Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential.

S. Pizzo, G. Salvesen, A. Mast, 1990, The Journal of laboratory and clinical medicine.

G. Virca, G D Virca, H P Schnebli, 1984, European journal of biochemistry.

Purification and properties of adenosine kinase from human tumor cells of type H. Ep. No. 2.

D. Hill, L. Bennett, H. Schnebli, 1967, The Journal of biological chemistry.

Crystal and molecular structure of the bovine α-chymotrypsin-eglin c complex at 2.0 Å resolution☆

Paolo Ascenzi, Martino Bolognesi, Alessandro Coda, 1992 .

Toxicity of oral iron chelator L1

P. Bentley, Heiner Frost, V. Berdoukas, 1993, The Lancet.

4-3,5-BIS(2-HYDROXYPHENYL)-1,2,4-TRIAZOL-1-YL-BENZOIC ACID : A NOVEL EFFICIENT AND SELECTIVE IRON(III) COMPLEXING AGENT

P. Acklin, B. Faller, U. Heinz, 1999 .

ICL670A: preclinical profile.

P. Acklin, B. Faller, Helmut Thomas, 2002, Advances in experimental medicine and biology.

Future of oral iron chelator deferiprone (L1)

F. Pfannkuch, P. Bentley, H. Schnebli, 1993, Lancet.

Concanavalin A as a tool

H. Bittiger, H. Bittiger, H. P. Schnebli, 1976 .

Reaction of lectins with human erythrocytes. III. Surface charge density and agglutination.

C. Roeder, L. Tarcsay, H. Schnebli, 1976, Experimental cell research.

The isolation of bacterial membrane ATPase and nectin.

C. Baron, A. Abrams, H. Schnebli, 1974, Methods in enzymology.

Reaction of lectins with human erythrocytes. IV. Details of adsorption and desorption of ConA.

M. Zulauf, A. Lustig, K. Winterhalter, 1977, Experimental cell research.

Reaction of lectins with human erythrocytes. I. Factors governing the agglutination reaction.

T. Bächi, H. Schnebli, 1975, Experimental cell research.

Demonstration of ricin-binding sites on the outer face of azurophil and specific granules of rabbit polymorphonuclear leukocytes

M. Baggiolini, H. Schnebli, M. E. Feigenson, 1975, The Journal of cell biology.

Conversion of 6-mercaptopurine and 6-mercaptopurine ribonucleoside to 6-methylmercaptopurine ribonucleotide in human epidermoid carcinoma no. 2. cells in culture.

L. Bennett, P. Allan, H. Schnebli, 1966, Biochimica et biophysica acta.

Reaction of lectins with human erythrocytes. II. Mapping of conA receptors by freeze-etching electron microscopy.

H. Schnebli, T. Bachi, 1975, Experimental cell research.

Crystal and molecular structure of the inhibitor eglin from leeches in complex with subtilisin Carlsberg

M. James, C. Mcphalen, M.N.G. James, 1985, FEBS letters.

Binding of the recombinant proteinase inhibitor eglin c from leech Hirudo medicinalis to serine (Pro)enzymes: A comparative thermodynamic study

M. Bolognesi, P. Ascenzi, E. Menegatti, 1991, Journal of molecular recognition : JMR.

Adjuvant-induced inflammatory disease in the rat: Plasma levels of peptide hydrolases and protease inhibitors reflect disease activity

H. Schnebli, 1979, Agents and Actions.

Plasma proteinase inhibitors.

H. Schnebli, J. L. Bodmer, 1984, Schweizerische medizinische Wochenschrift.

Kinetic studies on the interaction of eglin c with human leukocyte elastase and cathepsin G.

J. Bieth, G. Virca, R. Maschler, 1987, Biological chemistry Hoppe-Seyler.

Capping of concanavalin A- or ricin-binding sites does not influence phagocytosis in polymorphonuclear leukocytes

M. Baggiolini, H. Schnebli, M. E. Feigenson, 1976, Experientia.

Proteases and Protease Inhibitors in Neoplasia

H. Schnebli, 1974 .

A simple titration assay for anti-Concanavalin A sera

T. Bächi, H. Schnebli, 1975, Experientia.

Binding of concanavalin A and ricin to synaptic junctions of rat brain

H. Bittiger, H. Schnebli, 1974, Nature.

Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.

R. Crystal, C. Vogelmeier, R. Thompson, 1991, The Journal of clinical investigation.

Selective oxidation of methionyl residues in the human recombinant secretory leukocyte proteinase inhibitor. Effect on the inhibitor binding properties

M. Bolognesi, P. Ascenzi, D. Barra, 1994, Journal of molecular recognition : JMR.

X‐ray crystal structure of the bovine α‐chymotrypsin/eglin c complex at 2.6 Å resolution

M. Bolognesi, P. Ascenzi, F. Frigerio, 1990, Journal of Molecular Recognition.

Eglin-c, a polypeptide derived from the medicinal leech, prevents human neutrophil elastase-induced emphysema and bronchial secretory cell metaplasia in the hamster.

G. Snider, E. Lucey, J. Calore, 1985, The American review of respiratory disease.

Binding of the recombinant proteinase inhibitor eglin c from leech Hirudo medicinalis to human leukocyte elastase, bovine alpha-chymotrypsin and subtilisin Carlsberg: thermodynamic study.

M Bolognesi, M. Bolognesi, E. Menegatti, 1988, Journal of enzyme inhibition.

Preliminary crystallographic data on the complex of bovine alpha-chymotrypsin with the recombinant proteinase inhibitor eglin c from Hirudo medicinalis.

M. Bolognesi, E. Menegatti, G. Amiconi, 1989, Journal of molecular biology.

Release from density-dependent inhibition of growth in the absence of cell locomotion.

M. Yarnell, H. Schnebli, 1974, Journal of cell science.

Protease inhibitors do not block transformed cells in the G1 phase of the cell cycle

H. Schnebli, G. Haemmerli, 1974, Nature.

A protease-like activity associated with malignant cells.

H. Schnebli, 1972, Schweizerische medizinische Wochenschrift.

Selective oxidation of Met-192 in bovine alpha-chymotrypsin. Effect on catalytic and inhibitor binding properties.

M. Bolognesi, D. Barra, F. Cutruzzolà, 1993, Biochimica et biophysica acta.

Control of exogenous proteinases and their inhibitors at the macrophage cell surface.

R. Dean, H. Schnebli, 1989, Biochimica et biophysica acta.

"Flat" morphology induced in cultured transformed cells by polyphloroglucin phosphate.

H. Schnebli, M. Burger, 1973, Cancer Research.

Structure of the proteinase inhibitor eglin c with hydrolysed reactive centre at 2.0 Å resolution

Christian Betzel, Zbigniew Dauter, Jorge Navaza, 1993, FEBS letters.

A brief review of the biochemistry and pharmacology of Eglin c, an elastase inhibitor.

N. J. Braun, H. Schnebli, 1986, European journal of respiratory diseases. Supplement.

Development of Eglin c as a drug: pharmacokinetics.

H. Nick, H. Schnebli, A. Probst, 1988, Advances in Experimental Medicine and Biology.

The elastase/alpha 1-proteinase inhibitor balance in the lung. A review.

G. Virca, H. Schnebli, 1984, Swiss medical weekly.

Crystal and molecular structure of the bovine alpha-chymotrypsin-eglin c complex at 2.0 A resolution.

A Coda, M Bolognesi, M. Bolognesi, 1992, Journal of molecular biology.